
Microwave-Assisted Facile Synthesis and anticonvulsant evaluation of Novel N-(3-chloro-2-oxo-4-substituted phenyl azetidin-1-yl)-2-(1, 3-dioxoisoindolin-2-yl)acetamides

Mangesh S. Ghodke ^a, Anna Pratima G. Nikalje ^{b*}, Shailee V. Tiwari ^b, Julio A. Seijas ^c, M. Pilar Vazquez-Tato ^c

^a Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education & Research, Shirpur-425405,Dist. Dhule (MS)
^b Department Of Pharmaceutical Chemistry, Y. B. Chavan College Of Pharmacy, Dr. Rafiq Zakaria Campus, Aurangabad- 431003 (M.S.) India.
^c Departamento de Química Orgánica, Facultad de Ciencias, Universidad of Santiago De Compostela, Alfonso X el Sabio, Lugo 27002, Spain; julioa.seijas@usc.es (J.A.S.); pilar.vazquez.tato@usc.es (M.P.V.-T.)

*Corresponding author Email: annapratimanikalje@gmail.com Contact: +91 982361992

Graphical abstract



Abstract

Herewith, we report the design and synthesis of a series of N-(3-chloro-2phenyl azetidin-1-yl)-2-(1,3-dioxoisoindolin-2oxo-4-substituted yl)acetamide 7(a-1) derivatives, obtained by condensation of Schiff's base and chloroacetyl chloride in dimethyl formamide as solvent and few drops of triethyl amine as a catalyst under microwave irradiation for about 3-4 min (700 W) at 80°C based on four component pharmacophoric model to get structural prerequisite indispensable for anticonvulsant activity. The synthesized derivatives were investigated for CNS depressant, maximal electroshock seizure (MES), subcutaneous pentylenetetrazole (sc-PTZ) induced seizure and neurotoxicity screening. Most of the compounds were found to be potent in MES model. The anticonvulsant screening data shows that 65% of the compounds were found to be active against MES model when compared to 35% sc-PTZ model.

Keywords: Dioxoisoindolin-2-yl; Azetidinone; Microwave irradiation; Anticonvulsant evaluation; CNS depression.

Introduction:

Epilepsy is a chronic disorder affecting 50 million people worldwide [1–3]. It is characterized by recurrent seizures due to abnormal excessive and synchronous neuronal activity in the brain. Epilepsy, being one of the most common and serious neurological disorder is characterized by recurrent seizures which results from a temporary electrical disturbance of the brain due to an imbalance between excitatory and inhibitory neurotransmitters. About one third of the patients do not respond well to current multiple drug therapy [4, 5].

A global campaign against epilepsy conducted by World Health Organization (WHO) in partnership with International Bureau for Epilepsy (IBE) and International League against Epilepsy (ILAE) suggested that around 1% of world population at any time is afflicted with this neurological disorder [6, 7]. Phenytoin, carbamazepine, lamotrigine, sulfamate and topiramate are recent antiepileptic drugs which have been clinically effective against different types of seizures. Moreover, these drugs cause various side effects such as drowsiness, gastrointestinal disturbance, hepato-toxicity, and megaloblastic anemia.

Many researchers have investigated phthalimide and azetidinone moieties due to their potential anticonvulsant and CNS depressant activities [8-20]. On the basis of the above findings from literature survey and considering the need for the development of potent CNS active agents, in continuation to our earlier efforts in finding better, novel anticonvulsant agents [21-24] it was thought worthwhile to synthesize heterocyclic system containing phthalimide and azetidinone ring to give coupled derivatives having more potent anticonvulsant activity In the present work, our objective was to design and synthesize new compounds having dioxoindolin moiety coupled with azetidinone nucleus via amide linkage, as a pharmacophore, with the hope to get compounds with enhanced anticonvulsant activity. Thus, novel, N-(3-chloro-2-oxo-4substituted phenyl azetidin-1-yl)-2-(1,3-dioxoisoindolin-2-yl) acetamide 7(a-1) derivatives were synthesized as antiepileptic drugs that shows similar mode of action on neuronal sodium channels as phenytoin [25]. All the synthesized titled compounds comprised of the essential pharmacophoric elements that are necessary for good anticonvulsant activity as suggested by Unverferth et al. [26], which are indicated by rectangles in Fig. 1. The essential structural features which could be responsible for an interaction with the active site were a hydrophobic unit (R), an electron donor (D) group, and a hydrogen donor/acceptor (HBD) unit [27]. The title compounds were synthesized by microwave method as it gives less pollution, shorter reaction time, increased rate of reaction, more yield, cleaner and greener ecofriendly synthetic protocol. 6




Figure 1: Basic Structure of compound 7(a-l)

Results and discussions

Chemistry

The synthetic protocol employed for the synthesis of N-(3-chloro-2-oxo-4substituted phenyl azetidin-1-yl)-2-(1,3-dioxoisoindolin-2-yl)acetamide derivatives is presented in Scheme 1. N-substituted 7(a-1) benzylidene/methylene-2-(1,3-dioxo isoindolin-2-yl) acetohydrazides 6(a-1) was obtained as per procedure [28] which upon reaction with chloro acetyl chloride in DMF and using few drops of triethyl amine as a catalyst under microwave irradiation for about 3-4 min (700 W), gives final derivatives 7(a-1). The purity of the synthesized compounds was checked by TLC and melting points were determined in open capillary tubes on a Buchi 530 melting point apparatus and are uncorrected. The assignments of the structures were based on elemental and spectral data. The physical data of the synthesized compounds is presented in Table 1. The proposed structures of final compounds were confirmed by the data obtained from IR, NMR, Mass and 8 elemental analysis.

Anticonvulsant activity


A series of novel N-(3-chloro-2-oxo-4-substituted phenyl azetidin-1-yl)-2-(1, 3-dioxoisoindolin-2-yl) acetamide 7(a-l) were obtained under microwave irradiation in good yield and require shorter reaction times.

All the synthesized compounds were evaluated for their anticonvulsant activity by MES and sc-PTZ model and have shown best protection against MES test (Table 2). In MES test, the anticonvulsant activity of the newly synthesized compounds was carried out at 0.5 and 4 h at the dose of 100 mg/kg. The compounds 7a, 7d, and 7e have shown best protection at both time intervals. In MES test, the compounds 7b, 7c, 7g and 7h showed protection at 0.5 h, while compounds **7f**, **7i** and **7j** showed protection at 4 h. In sc-PTZ test (Table 2), among synthesized compounds, 7a, 7c, 7d and 7h showed protection at both intervals while compound 7a, 7e, 7f, 7i and 7j showed protection at 0.5 h at the dose 100 mg/kg.

Neurotoxicity screening

In neurotoxicity screening, the compounds **7a**, **7c**, **7d**, **7e**, **7g**, **7i** and **7j** were found to be nontoxic at a dose of 100 mg/kg while compounds **7b**, **7f**, **7h** and **7k** were found to be toxic at the same dose after 4 h (Table 2). Behavioural activity

From the behavioural activity of synthesized compounds using actophotometer, the compounds **7a**, **7c** and **7e** showed no behavioral despair effect when compared to diazepam at 0.5 h. The compounds **7a**, **7b**, **7e** and **7h** showed no behavioral despair effect when compared to diazepam at 4 h (Table 3). All the other compounds were found to decrease behavioral activity of the animals at 100 mg/kg compared to diazepam.



Scheme 1

Table 1: Physical constants data for N-(3-chloro-2-oxo-4-substituted phenyl azetidin-1-yl)-2-(1,3-dioxoisoindolin-2-yl)acetamide 7(a-l)

Code	Ar	Molecular formula	Mol. wt.	% Yield	Time (min)	M.P. ⁰ C	R _f value
7a		C ₁₉ H ₁₄ ClN ₃ O ₄	383.79	79	4	130-135	0.62
7b		$C_{19}H_{14}ClN_3O_5$	399.78	84	3	137-140	0.61
7c		$C_{20}H_{16}ClN_{3}O_{5}$	413.81	78	3.5	170-173	0.66
7d	⊸С⊢сн₃	$C_{20}H_{16}ClN_3O_4$	397.81	86	4.5	146-148	0.56
7e	——————————————————————————————————————	$C_{19}H_{13}Cl_2N_3O_4$	418.23	78	4	151-153	0.65
7f	F	$C_{19}H_{13}ClFN_3O_4$	401.78	68	3	140-142	0.78
7g		C ₂₂ H ₂₀ ClN ₃ O ₇	473.86	58	2	141-143	0.56
7h	- Он	$C_{19}H_{14}ClN_3O_5$	399.78	78	3	178-180	0.65
7i	ОСН ₃ ————————————————————————————————————	$C_{20}H_{16}ClN_3O_6$	429.81	75	2.5	162-165	0.55
7ј	ОС₂Н₅ —∕_ОН	$C_{21}H_{18}ClN_{3}O_{6}$	443.84	79	4	154-155	0.58
7k	\square	$C_{17}H_{12}ClN_{3}O_{5}$	373.75	82	4.5	130-134	0.46
71	s s	$C_{17}H_{12}ClN_3O_4S$	389.81	83	3.5	171-173	0.54

12

Comp.	MES Screen		Sc	PTZ	Neurotoxicity	
			Screen		Screen	
	0.5 h	4h	0.5 h	4h	4h	
7a	100	100	100	100	Non-toxic	
7b	100	N	100		Toxic	
7c	100		100	100	Non-toxic	
7d	100	100	100	100	Non-toxic	
7e	100	100	100		Non-toxic	
7 f	-	100	100		Toxic	
7g	100	1	No-		Non-toxic	
7h	100		100	100	Non-Toxic	
7i	14 - 1 ×	100	100	Sell-	Non-toxic	
7j	-	100	100		Non-toxic	
7k		- 1 A		5 A	Toxic	
71	200 <u>-</u> 200 -		No-Free		Non-toxic	
Phenytoin	100	100	Х	X	Х	

Table 2: Anticonvulsant and neurotoxicity screening of compounds

Dose 100 mg/kg of the compound was administered and the protection and neurotoxicity were measured after 0.5 and 4 h. The figures indicate the minimal dose required to cause protection or neurotoxicity in 50% or more of the animals. The dash (_) indicates the absence of anticonvulsant activity or neurotoxicity. (X) denotes not tested.

Table 3: Behavioural study of the synthesised compounds 7(a-l) using actophotometer

Comp.	Activity Score	Post Treatment ^a		
	Control	0.5h	4h	
	(24 h before			
7a	163.41±5.192	34.20±3.720**	27.60±2.015ns	
7b	115.79±4.294	85.20±5.305**	63.40±3.250ns	
7c	120.82±3.942	69.20±0.663**	51.40±9.522**	
7d	150.61±10.628	52.00±11.375ns	82.60±2.182**	
7e	135.59±6.547	99.60±3.265**	18.00±1.414ns	
7f	141.44±8.060	61.60±7.501**	63.40±5.240**	
7g	134.22±5.380	39.20±3.184ns	98.80±4.259**	
7h	110.63±5.60	73.00±3.715**	21.80±2.835ns	
7i	140.60±8.453	60.80±4.748**	42.20±12.265**	
7j	120.18±3.736	83.00±8.185**	72.00±11.459ns	
7k	118.41±2.731	102.60±9.770**	90.20±9.937ns	
71	138.63±3.076	101.60±2.713**	50.80±8.114ns	
Diazepam ^b	170.60±2.839	71.80±1	'1.80±13.309**	

Each value represents the mean SEM significantly different from the control at p<0.05; ns denotes not significant at p<0.05 (Student's t-test); locomotor activity score was measured for 10 min. ^{b)} The compound was tested at dose level of 4 mg/kg (i.p.).

Experimental

Chemistry

All reagents and solvents were used as obtained from the supplier or recrystallized/redistilled unless otherwise noted. Synthetic microwave oven Milestone micro synth system was used for synthesis of final title compounds. The progress of the reaction was monitored by TLC, silica gel-G (Merck) coated aluminium plates, visualized by iodine vapor. Infrared (IR) and nuclear magnetic resonance (¹H NMR and ¹³C NMR) spectra of the synthesized compounds were recorded on JASCO FTIR (PS 4000) using KBr pellets and Bruker Avance II (400MHz) instruments, respectively. Chemical shifts are reported in parts per million (ppm), using TMS as an internal standard. Elemental analyses (C, H, and N) were undertaken with a Shimadzu FLASHEA112 analyzer and all analyses were consistent with theoretical values (within $\pm 0.5\%$) unless indicated. The mass spectra were recorded on a Waters MicroMass ZQ 2000 spectrometer

General procedure for the preparation of N-substituted benzylidene/methylene-2-(1, 3-dioxo isoindolin-2-yl) acetohydrazides 6(al)

N'-Substituted benzylidene/methylene-2-(1, 3-dioxoisoindolin-2-yl) acetohydrazide 6a-l) were synthesized as per given procedure [28].
General procedure for the preparation of N-(3-chloro-2-oxo-4-substituted)

phenyl azetidin-1-yl)-2-(1,3-dioxoisoindolin-2-yl)acetamide 7(a-l)

In an Erlenmeyer flask compound Schiff base **6(a-1)** (0.01 mol) and DMF (15mL) were taken. To it chloro acetyl chloride (0.01 mol) and triethyl amine (0.01 mol) as a catalyst was added slowly. The reaction mixture was irradiated inside a synthetic microwave oven for about 3-4 min (700 W) at 80°C. After completion of reaction (monitored by TLC), mixture was poured into ice cold water. The solid product formed was filtered, dried and recrystallized from ethanol. The structures of the final compounds of the series **7(a-1)** were confirmed by the spectral data and elemental analysis as given below [32].

N-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-2-(1,3-dioxoisoindolin-2yl)acetamide (7a)

IR (KBr, u_{max} in cm⁻¹): 3333 (N-H of amide), 3011 (C-H of aromatic), 1770 (C=O of azetidinone), 1715, 1710 C=O of Phthalimide), 1675 C=O of amide), 1605 (C-C of aromatic), 1314 (C-N), 1280 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 4.6 (s,2H, -CH₂ of alkyl), 5.08 (s, 1H, -CH of lactam ring), 7.27 -7.91 (m, 4H, Ar-H), 9.2 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163, 143, 132, 128, 126, 123, 64,50; MS m/z: 382 (M+1); Anal. Calcd. for C₁₉H₁₄ClN₃O₄: C, 59.46; H, 3.68; Cl, 8.50; N, 10.95; Found: C, 59.40; H, 3.55; Cl, 8.47; N, 10.91.

N-(3-chloro-2-(2-hydroxyphenyl)-4-oxoazetidin-1-yl)-2-(1,3-dioxoisoindolin-2-yl) acetamide (7b)

IR (KBr, υ_{max} in cm⁻¹): 3330 (N-H of amide), 3014 (C-H of aromatic), 1769 (C=O of azetidinone), 1713, 1716 (C=O of Phthalimide), 1670 C=O of amide), 1610 (C-C of aromatic), 1310 (C-N), 1285 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 4.58 (s, 2H, -CH₂ of alkyl), 5.06 (s, 1H, -CH of lactam ring), 6.89-7.91 (m, 4H, Ar-H), 9.15 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163, 154, 132, 128, 126, 123, 121, 64, 61, 50; MS m/z: 398.78 (M+1); Anal. Calcd. for C₁₉H₁₄ClN₃O₅: C, 57.08; H, 3.53; Cl, 8.56; N, 10.51; Found: C, 57.01; H, 3.50; Cl, 8.54; N, 10.45.

N-(3-chloro-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl)-2-(1,3dioxoisoindolin-2-yl)acetamide (7c)

IR (KBr, v_{max} in cm⁻¹): 3335 (N-H of amide), 3012 (C-H of aromatic), 1770 (C=O of azetidinone), 1713, 1712 (C=O of Phthalimide), 1660 (C=O of amide), 1604 (C-C of aromatic), 1311 (C-N), 1277 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 3.28 (s, 3H, -OCH₃ of phenyl ring), 5.3 (s, 1H, -CH of lactam ring), 5.7 (s, 2H, -CH₂ of alkyl), 6.9-7.75 (m, 4H, Ar-H), 9.1 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 70, 168, 163, 158, 135, 132, 126, 123, 67, 64, 55, 50; MS m/z: 414 (M+1); Anal. Calcd. for C₂₀H₁₆ClN₃O₅: C, 58.05; H, 3.90; Cl, 8.57; N, 10.15; O, 19.33; Found: C, 58.10; H, 3.85; Cl, 8.55; N, 10.17.

N-(3-chloro-2-oxo-4-p-tolylazetidin-1-yl)-2-(1,3-dioxoisoindolin-2yl)acetamide (7d)

IR (KBr, v_{max} in cm⁻¹): 3327 (N-H of amide), 3009 (C-H of aromatic), 1766 (C=O of azetidinone), 1710, 1714 (C=O of Phthalimide), 1675 (C=O of amide), 1601 (C-C of aromatic), 1309 (C-N), 1287 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 2.18 (s, 3H, -CH₃ of phenyl ring), 4.6 (s,2H, -CH₂ of alkyl), 5.44 (s, 1H, -CH of lactam ring), 7.09 -7.98 (m, 4H, Ar-H), 9.16 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163, 140, 136, 132, 128, 125, 123, 67, 64, 50, 21; MS m/z: 397 (M+1); Anal. Calcd. for C₁₉H₁₄ClN₃O₄: C, 60.38; H, 4.05; Cl, 8.91; N, 10.56; Found: C, 60.34; H, 3.99; Cl, 8.93; N, 10.51.

N-(3-chloro-2-(4-chlorophenyl)-4-oxoazetidin-1-yl)-2-(1,3-dioxoisoindolin-2-yl)acetamide (7e)

IR (KBr, v_{max} in cm⁻¹): 3345 (N-H of amide), 3152 (C-H of aromatic), 1762 (C=O of azetidinone), 1703, 1719 (C=O of Phthalimide), 1640 (C=O of amide), 1609 (C-C of aromatic), 1314 (C-N), 1285 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 4.5 (s, 2H, -CH₂ of alkyl), 5.40 (s, 1H, -CH of lactam ring), 7.84 -7.91 (m, 4H, Ar-H), 9.16 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163, 141, 132, 128, 127, 123, 67, 64, 50; MS m/z: 418 (M+1); Anal. Calcd. for C₁₉H₁₃C₁₂N₃O₄: C, 54.56; H, 3.13; Cl, 16.95; N, 10.05;Found: C, 54.51; H, 3.08; Cl, 16.90; N, 10.01;

N-(3-chloro-2-(4-fluorophenyl)-4-oxoazetidin-1-yl)-2-(1,3-dioxoisoindolin-2-yl)acetamide (7f)

IR (KBr, v_{max} in cm⁻¹): 3340 (N-H of amide), 3160 (C-H of aromatic), 1756 (C=O of azetidinone), 1706, 1714 (C=O of Phthalimide), 1635 (C=O of amide), 1610 (C-C of aromatic), 1320 (C-N), 1281 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 4.5 (s, 2H, -CH₂ of alkyl), 5.40 (s, 1H, -CH of lactam ring), 7.84 -7.91 (m, 4H, Ar-H), 9.16 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163, 139, 132, 128, 123, 67, 64, 50; MS m/z: 402 (M+1); Anal. Calcd. for C₁₉H₁₃C₁₂N₃O₄: C, 54.56; H, 3.13; Cl, 16.95; N, 10.05; Found: C, 54.51; H, 3.08; Cl, 16.90; N, 10.01;

N-(3-chloro-2-oxo-4-(3,4,5-trimethoxyphenyl)azetidin-1-yl)-2-(1,3dioxoisoindolin-2-yl)acetamide (7g)

IR (KBr, υ_{max} in cm⁻¹): 3338 (N-H of amide), 3156 (C-H of aromatic), 1754 (C=O of azetidinone), 1710, 1717 (C=O of Phthalimide), 1640 (C=O of amide), 1625 (C-C of aromatic), 1317 (C-N), 1278 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 3.72 (s, 3H, -OCH₃ of phenyl ring), 4.60 (s, 2H, -CH₂ of alkyl), 5.10 (s, 1H, -CH of lactam ring), 6.65-7.90 (m, 4H, Ar-H), 9.05 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163, 152, 137, 132, 123, 68, 64, 56, 50; MS m/z: 473 (M+1); Anal. Calcd. for C₂₂H₂₀ClN₃O₇: C, 55.76; H, 4.25; Cl, 7.48; N, 8.87; Found: C, 55.72; H, 4.21; Cl, 7.43; N, 8.85;

N-(3-chloro-2-(4-hydroxyphenyl)-4-oxoazetidin-1-yl)-2-(1,3dioxoisoindolin-2-yl)acetamide (7h)

IR (KBr, v_{max} in cm⁻¹): 3497 (-OH stretching), 3335 (N-H of amide), 3152 (C-H of aromatic), 1754 (C=O of azetidinone), 1715, 1720 (C=O of Phthalimide), 1640(C=O of amide), 1625 (C-C of aromatic), 1310 (C-N), 1280 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 4.56 (s,2H, -CH₂ of alkyl), 5.15 (s, 1H, -CH of lactam ring), 6.71-7.92 (m, 4H, Ar-H), 9.1 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163, 156, 136, 132, 127, 123, 115, 67, 64, 50; MS m/z: 400 (M+1); Anal. Calcd. for C₁₉H₁₄ClN₃O₅: C, 57.08; H, 3.53; Cl, 8.87; N, 10.51; Found: C, 57.02; H, 3.48; Cl, 8.85; N, 10.49;

N-(3-chloro-2-(4-hydroxy-3-methoxyphenyl)-4-oxoazetidin-1-yl)-2-(1,3dioxoisoindolin-2-yl)acetamide (7i)

IR (KBr, u_{max} in cm⁻¹): 3457 (-OH stretching), 3345 (N-H of amide), 3015 (C-H of aromatic), 1750(C=O of azetidinone), 1720, 1722 (C=O of Phthalimide), 1640 (C=O of amide), 1610(C-C of aromatic), 1315 (C-N), 1280 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 4.18 (s, 3H, -OCH₃ of phenyl ring), 5.16 (s, 1H, -CH of lactam ring), 5.3 (s, 1H,-OH of aromatic ring), 5.8 (s, 2H, -CH₂ of alkyl),6.9 - 8.2 (m, 4H, Ar-H), 9.08 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163, 147, 146, 137, 132, 123, 119, 110, 67, 64, 50; MS m/z: 430 (M+1); Anal. Calcd. for C₁₉H₁₄ClN₃O₄: C, 55.89; H, 3.75; Cl, 8.25; N, 9.78; Found: C, 55.83; H, 3.71; Cl, 8.20; N, 9.72;

N-(3-chloro-2-(3-ethoxy-4-hydroxyphenyl)-4-oxoazetidin-1-yl)-2-(1,3dioxoisoindolin-2-yl) acetamide(7j)

IR (KBr, υ_{max} in cm⁻¹): 3450(-OH stretching), 3340 (N-H of amide), 3020 (C-H of aromatic), 1755 (C=O of azetidinone), 1715, 1720 (C=O of Phthalimide), 1638 (C=O of amide), 1617 (C-C of aromatic), 1320 (C-N), 1275 (N-N); ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 1.3 (s, 1H,-CH₃ of phenyl) 4.13 (dd, 2H, -CH₂ of phenyl ring), 5.08 (s, 1H, -CH of lactam ring), 4.55 (s, 2H, -CH₂ of alkyl), 7.84-7.91 (m, 4H, Ar-H), 9.13 (s, 1H, -NH) 9.80 (s, 1H, -OH); ¹³C NMR (100MHz DMSO, ppm): 170, 168, 163,148, 146, 132, 123, 115,110, 67, 64, 50, 14; MS m/z: 444(M+1); Anal. Calcd. for C₂₁H₁₈ClN₃O₆: C, C, 56.83; H, 4.09; Cl, 7.99; N, 9.47; Found: C, 56.77; H, 4.03; Cl, 7.94; N, 9.41.

N-(3-chloro-2-(furan-2-yl)-4-oxoazetidin-1-yl)-2-(1,3-dioxoisoindolin-2yl)acetamide (7k)

IR (KBr, u_{max} in cm⁻¹): 3329 (N-H of amide), 3009 (C-H of aromatic), 1765 (C=O of azetidinone), 1710, 1716 (C=O of Phthalimide), 1680 C=O of amide), 1615 (C-C of aromatic), 1316 (C-N), 1275 (N-N), ; ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 4.6 (s,2H, -CH₂ of alkyl),5.29 (s, 1H, -CH of lactam ring), 7.84 - 7.91 (m, 4H, Ar-H), 9.13 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170,168,163,151,141,132, 123,110,109,65,62,50;MS m/z: 374(M+1); Anal. Calcd. for C₁₇H₁₂ClN₃O₅: C, 54.63; H, 3.24; Cl, 9.48; N, 11.24;; Found: C, 54.59; H, 3.20; Cl, 9.42; N, 11.21;.

N-(3-chloro-2-oxo-4-(thiophen-2-yl) azetidin-1-yl)-2-(1,3-dioxoisoindolin-2-yl) acetamide (71)

IR (KBr, υ_{max} in cm⁻¹): 3331 (N-H of amide), 3010 (C-H of aromatic), 1775 (C=O of azetidinone), 1718, 1713 C=O of Phthalimide), 1670(C=O of amide), 1610 (C-C of aromatic), 1311 (C-N), 1282 (N-N), ; ¹H NMR (DMSOd₆, 400 MHz) δ ppm: 4.5 (s,2H, -CH₂ of alkyl),5.10 (s, 1H, -CH of lactam ring), 7.84 - 7.93 (m, 4H, Ar-H), 9.01 (s, 1H, -NH); ¹³C NMR (100MHz DMSO, ppm): 170,168,163,132,129,128,127,123, 64,50;MS m/z: 390 (M+1); Anal. Calcd. for C₁₇H₁₂ClN₃O₄S: C, 52.38; H, 3.10; Cl, 9.09; N, 10.78; Found: C, 52.33; H, 3.05; Cl, 9.04; N, 10.73.

Conclusion

By using green synthetic protocol we have been able to synthesize N-(3chloro-2-oxo-4-substituted phenyl azetidin-1-yl)-2-(1, 3dioxoisoindolin-2-yl) acetamide 7(a-l) derivatives under MW irradiation, by condensation of various Schiff base 6(a-1), DMF (15mL) chloro acetyl chloride and triethyl amine. in better yield, in shorter duration and to cause least pollution for investigation of anticonvulsant and CNS depressant activities. This was achieved by avoiding use of excessive solvents and by using synthetic microwave for faster reactions. The derivatives exhibited promising activity in MES and sc-PTZ test. The rotarod test was used for neurotoxicity evaluation and shows significant results. The various computational parameters studied include docking studies, log p calculation and prediction of ADME properties. The compounds 7c (R= methoxy), 7e (R= chloro) and 7h (R= hydroxy) was found to be most potent CNS depressant compounds. 23

The compounds 7d (R= methyl) 7e (R= chloro), 7h(R= hydroxy) have shown excellent anticonvulsant activity when compared with results of standard (** P< 0.01,*P<0.05). From correlation of activity with the structure of synthesized derivatives it has been observed that groups like electron donating group (7e) and (7d) attached to the phenyl ring increased CNS activity. In conclusion compound 7c, 7d, 7e, 7f, and 7h can be further optimized and developed as a lead molecule. Thus, N-(3chloro-2-oxo-4-substituted phenyl azetidin-1-yl)-2-(1,3dioxoisoindolin-2-yl)acetamide 7(a-l) have been obtained in good yield in an eco-friendly synthetic protocol and have exhibited potential anticonvulsant activity and can be developed as a lead molecule.

References

- [1] M.J. Brodie, S.D. Shorvon, R. Canger, P. Halász, S. Johannessen, P. Thompson, H.G. Wieser, P. Wolf, *Epilepsia* **1997**, 38,1245-50.
- [2] P. Kwan, M.J. Brodie, Eng J. Med. 2000, 342,314-19.
- [3] World Health Organization: Epilepsy Fact Sheet No. 999. World Health Organization (WHO); 2012.
- http://www.who.int/ mediacentre/factsheets/fs999/en/index.html]
- [4] WHO data obtained from.
- http://www.who.int/mediacentre/factsheets/fs165/en/.
- [5] D. Schmidt, W. Loscher, Epilepsia, 2005, 46, 858-877.
- [6] Secretariats of WHO/IBE/ILAE, Global Campaign Against Epilepsy, Atlas: Epilepsy Care in the World, Programme for Neurological Diseases and Neuroscience. Department of Mental Health and Substance Abuse, World Health Organization, Geneva, 2009. http://www.who. int/entity/mediacentre/factsheets/fs999/en epilepsy cmpaign/en

- [7] Annual report of the WHO/IBE/ILAE, Global Campaign Against Epilepsy: Out of the Shadows,
- 2003.http://www.who.int/entity/mentalhealth/management/ global epilepsy cmpaign/en
- [8] M.A. Bhat, M. A. Al-Omar, Acta Poloniae Pharmaceutica Drug Research,2011, 68(3), 375-380.
- [9] N. Yadav, M. Malhotra, V. Monga, S. Sharma, J. Jain, *Med. Chem. Res.*2012, 21,2208–2216.
- [10] V. Kathuria, D.P. Pathak, The Pharma Innovation, **2012**, 1(10), 55-59.
- [11] S.A. Khan, N. Siddiqui, M. Kamal, O. Alam, T. Jawaid, Acta Polon.
- Pharma. Drug Res. 2009, 66, 65-68.
- [12] K. Gerhard, C. O. Usifoha, D. M. Lambertc, J. Woutersd, E. Scribaa, Arch.Pharm. Med. Chem., 2001,334, 323–331.
- [13] S.K. Srivastava, S. Srivastava, S.D. Srivastava, Ind. J. Chem., **1999**, 38B,183-187.
- [14] R. Ali, N. Siddiqui, Arch. Pharm. Chem. Life. Sci., 2015, 348, 254–26526

- [15] H. Hasan, M. Akhter, W. Akhter, Ali Israr, Med. Chem. Res. 2011, 20,1357–1363.
- [16] K.D. Singh, S. Sood, A. Muthuraman.*Med. Chem. Res.*, **2012**, 21,2300–2306
- [17] P.Y. Pawar, S. U. Kalure, R. B. Kulkarni, Int. J. Pharm. Pharm. Sci., 2011,4(5), 464-467.
- [18] A. P. G. Nikalje, M. S. Ghodke, S. Mirza, WJPPS, **2014**, 3(2), 2589-2625
 [19] K.R. Desai, B. Naik, Ind. J. Chem. **2006**, 45, 267-271.
- [20] H. Kaur, S.Kumar, A. Chaudhary, A. Kumar, Arabian J. Chem., **2012**, 5, 271–283
- [21] A. P. Nikalje, A. Ansari, S. Bari, V. Ugale, Arch. Pharm. Chem. Life Sci. **2015**, 348, 1–13

- [22] A. P. G. Nikalje, S. I. Shaikh, A. Mulay, F. A. K. Khan, J.N. Sangshetti, S.Shaikh, Arch. Pharm. Chem. Life Sci. 2014, 347, 1–12
- [23]A.P. G. Nikalje, A. N. Shaikh, S.I. Shaikh, F.A. K.Khan, J.N. Sangshetti, D.
- B.Shinde, Bioorg. Med. Chem. Lett. 2014,24, 5558-5562
- [24] A. P. G. Nikalje, S.I. Shaikh, F. A. K. Khan, S. Shaikh, J.N. Sangshetti, Med. Chem. Res. 2015, 24, 4058–4069
- [25] A.W. Yuen, Epilepsia 1994, 35, 5, S33-S36.
- [26] K. Unverferth, J. Engel, N. Hofgen, A. Rostock, R. Gunther, H.J. Lankau,
 M. Menzer, A. Rolfs, J. Liebscher, B. Muller, H.J. Hofmann, *J. Med. Chem.* **1998**, 41,63-73.
- [27] X. Ma, T.Y. Poon, P.T.H. Wong, W.K. Chui, *Bioorg. Med. Chem. Lett.* **2009**, 19,5644-5647.
- [28] A. P. G. Nikalje, M. Ghodke, F. K. Khan, Eur. J. Med. Chem. 2011, 46, 5448-5455
- [29] K.G.Desai, K.R. Desai, J. Sulfur. Chem., 2006, 27,315-328.

Thank You